<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801137</url>
  </required_header>
  <id_info>
    <org_study_id>2010/23</org_study_id>
    <nct_id>NCT01801137</nct_id>
  </id_info>
  <brief_title>The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium</brief_title>
  <acronym>AFINIVEST</acronym>
  <official_title>A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <brief_summary>
    <textblock>
      A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients
      with transitional cell carcinoma of the urothelium which failed or progressed after two lines
      of chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 12 weeks</measure>
    <time_frame>3 months</time_frame>
    <description>If a patient has not had an event, Progression-free survival is censored at the date of last adequate tumor assessment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Afinitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by Afinitor 10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (Afinitor®)</intervention_name>
    <arm_group_label>Afinitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Male or female aged more than 18 years

          -  Histologically proven transitional cell carcinoma of the urothelium

          -  Metastatic or locally advanced disease not amenable to curative surgery and/or
             radiotherapy

          -  Recurrence or progression after at least one chemotherapy regimen and for
             unresectable/advanced disease

          -  No more than 2 lines of previous chemotherapy..

          -  Measurable disease (RECIST criteria)

          -  Previously irradiated lesions are not considered measurable- ECOG performance status
             of 0, 1 or 2

        Exclusion Criteria:

          -  No prior treatment with anti cancer agents, including radiotherapy, in the last 4
             weeks.

          -  No currently active CNS involvement

          -  No pregnancy. Women of child bearing potential must have a negative pregnancy test.

          -  No uncontrolled diabetes

          -  No symptomatic coronary artery disease, myocardial infarction within the last six
             months, congestive cardiac failure greater than New York Heart Association (NYHA)
             class II, uncontrolled or symptomatic cardiac arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <state>Ile de France</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

